
NASDAQHealthcareBiotechnology
ข้อมูลล่าสุด
US$72.46
+US$0.01 · +0.01%
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
ณ ราคาปิด
US$72.46
+US$0.01 · +0.01%
หลังปิดตลาด
US$72.46
US$0.00 · 0.00%
9 ต.ค. 16:04 ET
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
ช่วงราคารายวัน
ปัจจุบัน US$72.46
ช่วง 52 สัปดาห์
ปัจจุบัน US$72.46
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ถือ
มูลค่า
48
มูลค่ายุติธรรม
ความเชื่อมั่น
58
ผสม
ความเสี่ยง
41
ความเสี่ยงค่อนข้างสูง
โมเมนตัม
62
กำลังแข็งแกร่งขึ้น
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
ช่วงราคารายวัน
ปัจจุบัน US$72.46
ช่วง 52 สัปดาห์
ปัจจุบัน US$72.46
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (USD) | ปีงบประมาณ 2026 | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 |
|---|---|---|---|---|---|
| รายได้ | 1.22B USD | 1.22B USD | 1.16B USD | 1.14B USD | 1.11B USD |
| ต้นทุนสินค้าขาย | 415.97M USD | 429.36M USD | 389.34M USD | 366.89M USD | 349.1M USD |
| กำไรขั้นต้น | 799.07M USD | 790.27M USD | 769.73M USD | 769.82M USD | 756.5M USD |
| การวิจัยและพัฒนา | 94.77M USD | 99.5M USD | 96.66M USD | 92.49M USD | 87.14M USD |
| การขาย ทั่วไป และธุรการ | 452.42M USD | 415.1M USD | 393.32M USD | 352.44M USD | 339M USD |
| ค่าใช้จ่ายในการดำเนินงาน | 547.18M USD | 688.02M USD | 563.04M USD | 470.87M USD | 459.91M USD |
| รายได้ดอกเบี้ย | — | 3.89M USD | 3.32M USD | 3.41M USD | 794K USD |
| ดอกเบี้ยจ่าย | 5.41M USD | 8.51M USD | 15.74M USD | 11.22M USD | 11.31M USD |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 97.36M USD | 109.9M USD | 111.71M USD | 107.24M USD | 101.07M USD |
| รายได้จากการดำเนินงาน | 251.89M USD | 102.26M USD | 206.69M USD | 298.94M USD | 296.59M USD |
| รายได้สุทธิ | 181.86M USD | 73.4M USD | 168.11M USD | 285.26M USD | 272.05M USD |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 9 ต.ค. 2569.
ผลที่ประกาศแล้วพร้อมประมาณการร่วมที่มีอยู่
ผลที่ประกาศแล้วพร้อมประมาณการร่วมที่มีอยู่
กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
State Street SPDR S&P 500 ETF1557.T22.12B0.02%129.69T JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI360.03M0.02%2.3T USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO300.79M0.02%1.8T USD0.03%US$715.59+0.61%
Vanguard Morningstar Small-Cap ETFVB260.48M0.14%185.3B USD0.03%US$289.48+0.64%
Invesco S&P 500 Equal Weight ETFRSP195.84M0.20%96.2B USD0.20%US$213.04+0.55%
iShares Core S&P 500 ETFIVV151.03M0.02%897.2B USD0.03%US$781.97+0.60%
Vanguard Morningstar Small-Cap Growth ETFVBK149.52M0.33%44.7B USD0.05%US$344.74+1.22%
State Street SPDR S&P 500 ETFSPY139.8M0.02%821.54B USD0.09%US$778.57+0.60%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Small-Cap ETFVB
Invesco S&P 500 Equal Weight ETFRSP
iShares Core S&P 500 ETFIVV
Vanguard Morningstar Small-Cap Growth ETFVBK
State Street SPDR S&P 500 ETFSPYเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน